Merck is hoping that Mavenclad’s regimen of dosing on five consecutive days in the first month and up to five consecutive days in the second month, with no need to dose again for a year, will ...

The list price of Mavenclad is around £2,050 per 10mg tablet, although, Merck is providing it to the NHS in England at a ...

The health service is thought to be the first in Europe to widely rollout cladribine, also known as Mavenclad and made by ...

Merck KGaA’s Mavenclad (cladribine) tablets have been recommended by the National Institute for Health and Care Excellence (NICE) to treat a broader group of multiple sclerosis (MS) patients. The ...

With approval of the highly convenient although side effect-challenged oral MS therapy Mavenclad in the EU (2017) and US (2019), we expect Merck to continue gaining share in the MS market.

The National Institute for Health and Care Excellence (NICE) has recommended cladribine (Mavenclad, Merck Serono) for adults in England with relapsing-remitting multiple sclerosis (RRMS).

Merck is looking for new assets as one of its key growth drivers, multiple sclerosis drug Mavenclad, will face patent expiry in 2026. The German company’s goal is to achieve a 50-50 split ...

The Merck KGaA company collaborated with actress and patient advocate Selma Blair for the I Was Ready for Change campaign.

US pharma group Merck said the UAE Ministry of Health and Prevention has approved the registration of its Mavenclad (cladribine tablets) for the treatment of adult patients with highly active ...

Healthcare sales rose 6.2%, driven by high demand for Merck’s main growth-driver metastatic cancer drug Erbitux, its multiple sclerosis treatment Mavenclad and its cardiovascular, metabolism and ...

The Scottish Medicines Consortium is reviewing cladribine for broader use in relapsing forms of the condition.

(Bloomberg) — Merck KGaA forecast rising profit this year as its life ... The pharma unit mainly relies on cancer drug Erbitux and multiple sclerosis treatment Mavenclad for growth, with the latter ...